Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is actively engaged in the voluntary delisting process. The firm was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.
P/E (price / listing EPS) Forward revenue growth (NTM)